Literature DB >> 20099672

[Total hip arthroplasty after avascular necrosis due to sickle cell disease in Senegal: series of 48 replacements].

M Sene1, A Dansoko, A Ndiaye, E Mbaye, C D Niang, M Faye.   

Abstract

The purpose of this study is to describe the outcome of total hip arthroplasty for management of aseptic osteonecrosis of the femoral head due to sickle cell disease. This consecutive series carried out over a 7-year period in 38 patients with a sickle-cell anaemia includes a total of 48 cemented prosthesis. The mean follow-up period was 5 years. Arthroplasty restored normal hip function (PMA score = 18) in 64% of cases. In 32% of cases the PMA score was more than 15. Pain was greatly reduced with total relief being achieved in 94% of cases. Walking ability also improved with 85% of patients having an unlimited walking distance. Radiological examination demonstrated edging on 36% of cupulas and 29% of the shafts. Complications were observed in 19% of cases. The main complications were loosening and dislocation of the prosthesis. Although the complication rate was high, functional outcomes in this series were good. These findings indicate that arthroplasty should be considered as the treatment of choice for aseptic osteonecrosis due to stage 3 and 4 sickle-cell disease in young patients. Use of uncemented implant and type of frictional torque are discussed.

Entities:  

Mesh:

Year:  2009        PMID: 20099672

Source DB:  PubMed          Journal:  Med Trop (Mars)        ISSN: 0025-682X


  2 in total

1.  Short term results of cementless total hip arthroplasty in sicklers.

Authors:  Yash Gulati; Mrinal Sharma; Bhupendra Bharti; Vibhu Bahl; Ishwar Bohra; Amit Goswani
Journal:  Indian J Orthop       Date:  2015 Jul-Aug       Impact factor: 1.251

2.  Total Hip Arthroplasty in a Low-Income Country: Ten-Year Outcomes from the National Joint Registry of the Malawi Orthopaedic Association.

Authors:  Simon Matthew Graham; Nicholas Howard; Chipiliro Moffat; Nicholas Lubega; Nyengo Mkandawire; William J Harrison
Journal:  JB JS Open Access       Date:  2019-12-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.